Nuvation Bio (NUVB) Competitors

Scholar Rock (NASDAQ:SRRK) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment, community ranking and dividends.

Do insiders & institutionals believe in SRRK or NUVB?

91.1% of Scholar Rock shares are owned by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are owned by institutional investors. 13.3% of Scholar Rock shares are owned by company insiders. Comparatively, 29.9% of Nuvation Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Do analysts rate SRRK or NUVB?

Scholar Rock currently has a consensus target price of $42.67, suggesting a potential upside of 28.05%. Nuvation Bio has a consensus target price of $7.83, suggesting a potential upside of 332.78%. Given Nuvation Bio's stronger consensus rating and higher possible upside, analysts plainly believe Nuvation Bio is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14
Nuvation Bio	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.17

Does the MarketBeat Community believe in SRRK or NUVB?

Scholar Rock received 112 more outperform votes than Nuvation Bio when rated by MarketBeat users. However, 80.82% of users gave Nuvation Bio an outperform vote while only 66.54% of users gave Scholar Rock an outperform vote.

Company	Underperform	Outperform
Scholar Rock	Outperform Votes 171 66.54%	Underperform Votes 86 33.46%
Nuvation Bio	Outperform Votes 59 80.82%	Underperform Votes 14 19.18%

Is SRRK or NUVB more profitable?

Nuvation Bio's return on equity of -21.89% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-145.60%	-91.83%
Nuvation Bio	N/A	-21.89%	-17.86%

Which has more volatility and risk, SRRK or NUVB?

Scholar Rock has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500. Comparatively, Nuvation Bio has a beta of 1.37, suggesting that its stock price is 37% more volatile than the S&P 500.

Does the media refer more to SRRK or NUVB?

In the previous week, Nuvation Bio had 13 more articles in the media than Scholar Rock. MarketBeat recorded 16 mentions for Nuvation Bio and 3 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 1.28 beat Nuvation Bio's score of 0.50 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvation Bio	6 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has preferable earnings and valuation, SRRK or NUVB?

Nuvation Bio has lower revenue, but higher earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	$33.19M	95.32	-$165.79M	-$2.53	-13.17
Nuvation Bio	$10.96M	56.21	-$75.80M	-$2.35	-0.77

Summary

Nuvation Bio beats Scholar Rock on 11 of the 17 factors compared between the two stocks.